← All indications
Eosinophilic Esophagitis
Chronic ESOPHAGITIS characterized by esophageal mucosal EOSINOPHILIA. It is diagnosed when an increase in EOSINOPHILS are present over the entire esophagus. The reflux symptoms fail to respond to PROTON PUMP INHIBITORS treatment, unlike in GASTROESOPHAGEAL REFLUX DISEASE. The symptoms are associated with IgE-mediated hypersensitivity to food or inhalant allergens.
Drugs by status
Phase 4 trials (6)
Phase 3 trials (8)
Phase 2 trials (19)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (19)
- Ception
- Regeneron
- Cephalon
- Shire
- AstraZeneca
- Sanofi
- Allakos, Inc.
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Dr. Falk Pharma GmbH
- Cancer Research Network
- Medical College of Wisconsin
- Mayo Clinic
- University of Cincinnati
- University of North Carolina at Chapel Hill
- EMS S/A
- National Center for Advancing Translational Science (NCATS)
- Adare Pharmaceuticals
Organization Involved with Phase 2 Indications (33)
- Meritage Pharma
- Celgene
- Forest Laboratories
- Novartis
- Arena Pharmaceuticals
- DBV Technologies
- GlaxoSmithKline
- Oxagen Ltd
- Vastra Gotaland Region
- University of Pennsylvania
- University of Arizona
- Baylor University
- Harvard University
- Indiana University
- Northwestern University
- Ohio State University
- Rhode Island Hospital
- Swiss EE Study Group
- Tufts University
- University of Iowa
- University of Bern
- University of California, Irvine
- University of California, San Diego
- University of Utah
- Vanderbilt University
- Virginia Polytechnic Institute and State University
- University of Basel
- Children's Center for Digestive Health
- Options Health Research, LLC
- Swiss EoE Research Group
- +3 more
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (2)